Table 2 Difference in standardized mortality rates according to intraoperative inotrope treatment
Statistical model | Number of patients | Standardized risk difference (%)(95% CI) | p value |
|---|---|---|---|
Main analyses | |||
 Crude 30-day mortality, milrinone vs dobutamine | 1452 | 4.2 (1.6; 6.8) | < 0.01 |
 Adjusted 30-day mortality, milrinone vs dobutamine | 1452 | 4.1 (1.2; 6.9) | < 0.01 |
 Crude 1-year mortality, milrinone vs dobutamine | 1452 | 6.1 (2.2; 10.1) | < 0.01 |
 Adjusted 1-year mortality, milrinone vs dobutamine | 1452 | 4.8 (0.4; 9.2) | 0.03 |
Sensitivity analyses on subpopulations | |||
 Adjustment for anesthetist’s preference of milrinone | |||
  Crude 30-day mortality, milrinone vs dobutamine | 817 | 7.4 (4.4; 10.3) | < 0.01 |
  Adjusted 30-day mortality, milrinone vs dobutamine | 817 | 6.2 (2.7; 9.6) | < 0.01 |
 Adjustment for hemodynamic status prior to cardiopulmonary bypass | |||
  Crude 30-day mortality, milrinone vs dobutamine | 533 | 2.1 (−2.2; 6.4) | 0.34 |
  Adjusted 30-day mortality, milrinone vs dobutamine | 533 | 1.4 (−3.6; 6.4) | 0.59 |
Centers analyzed separately | |||
 Crude 30-day mortality Aarhus, milrinone vs dobutamine | 726 | 3.4 (−0.1; 6.9) | 0.06 |
 Adjusted 30-day mortality Aarhus, milrinone vs dobutamine | 726 | 3.7 (−0.2; 7.5) | 0.06 |
 Crude 30-day mortality Aalborg, milrinone vs dobutamine | 644 | 6.5 (2.7; 10.3) | < 0.01 |
 Adjusted 30-day mortality Aalborg, milrinone vs dobutamine | 644 | 6.2 (2.3; 10.2) | < 0.01 |